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A molecular assay to quantify Mycobacterium tuberculosis is described. In vitro, 98% (n  96) of sputum
samples with a known number of bacilli (107 to 102 bacilli) could be enumerated within 0.5 log10. In comparison
to culture, the molecular bacterial load (MBL) assay is unaffected by other microorganisms present in the
sample, results are obtained more quickly (within 24 h) and are seldom inhibited (0.7% samples), and the MBL
assay critically shows the same biphasic decline as observed longitudinally during treatment. As a biomarker
of treatment response, the MBL assay responds rapidly, with a mean decline in bacterial load for 111 subjects
of 0.99 log10 (95% confidence interval [95% CI], 0.81 to 1.17) after 3 days of chemotherapy. There was a
significant association between the rate of bacterial decline during the same 3 days and bacilli ml1 sputum
at day 0 (linear regression, P  0.0003) and a 3.62 increased odds ratio of relapse for every 1 log10 increase
in pretreatment bacterial load (95% CI, 1.53 to 8.59).
Monitoring response to tuberculosis chemotherapy rapidly
and cheaply would be of enormous benefit in patient manage-
ment by identifying those failing therapy (30) and would open
up the possibility of shorter, less expensive trials based on its
use as a surrogate marker (24). At present, the only widely
accepted biomarker of treatment response is culture negativity
56 days after the commencement of therapy (18). Some au-
thors have suggested that measuring the decline in the bacte-
rial load may permit the outcome of treatment to be predicted
more accurately (4, 8).
Currently available methods for measuring bacterial load have
significant drawbacks. Sputum smears are rapid and cheap but
have a sensitivity limit of 104 bacteria ml1 sputum (13) and
cannot differentiate between live and dead bacilli. Liquid cul-
ture methods for sputum bacterial load enumeration require
decontamination, and this reduces the mycobacterial count,
possibly in an uncontrolled way. The time to positivity of liquid
cultures is dependent on the bacterial burden of the sputum
inoculum, and therefore those samples negative by smear are
likely to take the longest to be determined culture positive.
Information is therefore not available quickly enough to aid
clinical decision making.
Sputum serial colony counting (SSCC) using selective solid
media does not require decontamination but requires exten-
sive laboratory operator time, the Mycobacterium tuberculosis
colonies grow slowly, and there is difficulty in obtaining single
colonies due to bacterial cording. Additionally, we have found
that selective media can reduce the colony count by around 1
log10 (our unpublished data). All culture-based methods are
affected by contamination with other microorganisms present
in the sample and viable noncultivatable M. tuberculosis organ-
isms. Publications over the last few years have demonstrated
that a significant proportion of viable organisms do not multi-
ply on artificial medium without the addition of resuscitation
promotion factors (22, 26).
Mycobacterial DNA can be detected in sputum samples
derived from patients that are culture negative (11, 14, 20),
whereas studies have found that RNA species have a shorter
half-life (11). Previous reports have suggested that abundant
mRNA species such as fbpB-85B and icl may be useful for the
detection of live bacilli (5, 9, 10, 15). While the clearance of the
icl gene showed promise as a biomarker for a fall in CFU at 7
days, it did not match liquid culture sensitivity at day 56. We
investigated the use of 16S rRNA due to its cellular abundance
and an expected half-life shorter than that of DNA. Data from
some studies imply that mycobacterial rRNA would respond
rapidly to bacterial cell death (21, 27, 29).
This study reports the development and evaluation of an
assay detecting M. tuberculosis 16S rRNA with a robust, novel
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internal control (IC) which normalizes for RNA loss during
extraction and the presence of sample inhibitors. The method,
which we have termed the molecular bacterial load (MBL)
assay, could be used to monitor tuberculosis treatment re-
sponse in the clinic and the clinical trials setting.
MATERIALS AND METHODS
Preparation of internal control. A 1,957-bp internal control (IC) was prepared
using in vitro transcription. For further details, see Table S1 and Data S1 in the
supplemental material. Serial dilutions of the internal control were performed
and spiked into sputum in a one-off experiment to ascertain the optimal con-
centration.
Correlation between novel IC and M. tuberculosis 16S rRNA for sputum sam-
ples spiked with a known concentration of M. tuberculosis. Fifty-one M. tubercu-
losis-negative sputum samples collected at the Royal Free Hospital, NHS Trust,
London, were used. These were already diluted with an equal volume of Sputasol
(Oxoid), and 1-ml aliquots were spiked with 107 M. tuberculosis bacilli from an
exponential culture of H37Rv (NTCC 7416). M. tuberculosis was cultured in 7H9
medium (BD) containing 0.2% Tween 80 during incubation (cultures were
passed 5 times through a needle, prior to use, to reduce clumping). Bacteria were
quantified by a modified Miles and Misra method as described previously (17).
These spiked sputa were treated with 5 ml of 5 M guanidine thiocyanate (GTC)
containing 0.7% -mercaptoethanol and kept at room temperature for 2 h before
being frozen at 80°C. Samples were kept frozen until RNA was extracted.
Determining the detection range for the MBL assay range using sputum
samples spiked with concentration known of tuberculosis. Fifteen tuberculosis-
negative sputa were obtained at the Royal Free Hospital, NHS Trust, London.
One-milliliter aliquots (obtained diluted with an equal volume of Sputasol, Ox-
oid) of each were spiked with a dilution series (107 to 100) of Mycobacterium
tuberculosis strain H37Rv (grown as detailed above). A negative control where
100 l of sterile water was added instead of bacterial culture was also included.
Samples were fixed in GTC as detailed below.
Patient cohort. Subjects with active pulmonary tuberculosis were recruited in
primary health care tuberculosis clinics in the Western Cape Province, South
Africa, following full local ethical approval. Patients consented to be involved in
the study. Full details of the patients in this cohort and the drug treatment
regimen have been reported previously (12). Longitudinal samples were col-
lected for 112 subjects. Details of how patient data were used are given in Fig. 1.
One hundred patients studied were cured following treatment and 12 patients
went on to relapse. Relapse patients were defined as those who were culture
negative at 6 months but in whom tuberculosis disease was found to have
recurred with the same M. tuberculosis strain as in the initial disease episode
during the 2 year follow-up. One day 0 sputum was negative for 16S rRNA. This
individual was excluded from the analysis since the patient was acid-fast bacillus
(AFB) positive by standard microbiology (liquid culture and Ziehl-Neelsen stain-
ing) and would bias the results in the favor of the reported observations com-
paring relapse and cure.
RNA preservation. Assay optimization control sputum samples, artificially
spiked with serially diluted H37Rv, as detailed below, were treated with 5 ml of
5 M GTC (Promega) also containing 17 mM N-lauroylsarcosine sodium salt, 25
mM trisodium citrate (pH 7.0 with 1 M HCl), 1% Tween 80, and 0.7% -mer-
captoethanol to preserve the RNA.
Two patient sputum samples were collected in the clinic at each time point.
The entirety of the first sample was used for routine bacteriology and the entirety
of the second was transferred into 4 M GTC, 0.1 M Tris-HCl (pH 7.5), and 1%
-mercaptoethanol immediately after expectoration in order to preserve the
M. tuberculosis RNA. Samples were transferred to the laboratory within 2 h and
then frozen at 80°C until RNA extraction. Details of routine bacteriology
processing for smear and liquid culture are outlined in the work of Hesseling
et al. (12).
RNA extraction and preparation. Patient sputum samples in GTC were ad-
justed accordingly so that the RNA extraction was from a total volume of 0.5 to
1.5 ml of sputum. Following thawing, 50 ng of the internal control was spiked into
each sputum sample and RNA extracted. Sputum containing RNA in GTC plus
the internal control (IC) was centrifuged at 2,000  g for 30 min at room
temperature. The supernatant was discarded, the pellet was agitated, and 1 ml of
RNApro (FastRNA Pro Blue kit; MP Biomedicals) was added. The manufac-
turer’s instructions from the RNApro kit were then followed for the remainder
of the extraction. Contaminating DNA was removed by treating with DNase I
(TURBO DNA-free kit; Ambion) according to the manufacturer’s instructions.
RT-qPCR. Expression of 16S-ROX and IC-Joe was measured using multiplex
reverse transcriptase (RT)-quantitative PCR (qPCR) (see Table S1 in the sup-
plemental material for detailed information on primer and probe sequences and
Data S2 for information about assay specificity). All reagents were from the
Quantitect Multiplex RT-PCR NR kit (Qiagen), except primers and dual-labeled
probes, which were synthesized by Eurofins MWG Operon. For details about
assay setup, see Data S3.
Nonlinear model fitting. Monoexponential and biexponential nonlinear mod-
els have been proposed to describe the decline in bacterial load over the first 2
months of treatment, with the biexponential model, reflecting two separate
phases of decline, having been shown to best fit the data (4, 8, 25). To compare
FIG. 1. Flowchart of in vitro and ex vivo sputum samples used in this study.
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the decline of the MBL assay-determined bacterial load in this study with the
decline of bacterial load reported in other published studies, we used the same
methods described in references 4 and 25 to fit and compare different nonlinear
models. Nonlinear mixed-effects models were therefore used to analyze the
decline in counts in the 111 patients. Models were fit using the nlme package in
R (www.r-project.org). Mono-, bi-, and triexponential models were compared
corresponding to one, two, or three phases of bacterial clearance, respectively.
The full specification of the models used can be found in reference 25. A
patient’s first zero count was replaced with a value of 5 bacilli ml1 sputum, with
any subsequent zero counts excluded from the analysis using the approach
described by Rustomjee et al. (25). Nonlinear models were compared using the
likelihood ratio test and the Akaike information criterion (AIC). For calculation
of bacterial decline transition times, see Data S4 in the supplemental material.
RESULTS
Determination of a standard curve for the molecular count.
Preliminary experiments were performed to establish the ef-
fective range and reproducibility of the molecular bacterial
load (MBL) assay. Studies of extraction efficiency revealed that
a 50-ng starting quantity of the internal control (IC) resulted in
an optimal cycle threshold (CT) of 16.00 when detected in a
multiplex RT-qPCR assay (data not shown). A total of 51 sputa
were each spiked with 107 bacilli and 50 ng of IC. This was
performed to ascertain whether variation in RNA extraction
and different inhibitors in sputum samples affected the gene of
interest (tuberculosis complex-specific 16S rRNA) and the in-
ternal control similarly. RNA was extracted from each and
then the cycle threshold (CT) was measured using RT-qPCR
for 16S rRNA and IC. Using linear regression, the coefficient
of determination, R2, was determined to be 0.84 (Fig. 2a).
Since the inhibition and RNA loss for the IC and gene of
interest correlated closely, we were able to normalize the re-
sults obtained for the 16S with the IC result for RNA extracted
from sputum. According to the relationship between the IC
and 16S rRNA (Fig. 2a), the equation for normalization of 16S
rRNA is given as follows: 16S rRNA CT  [(IC CT  16.00) 
0.7834]. (A CT of 16.00 represents the lowest possible inhibi-
tion/RNA loss as determined empirically and 0.7834 is the
slope of the line (Fig. 2a).
Detection limit of the MBL assay was determined in vitro as
102 bacteria ml1 sputum. Preliminary experiments were per-
formed to establish the effective range and specificity of the
MBL assay. The range in cycle threshold for 16S rRNA ex-
pression, determined as described above, was compared at
each bacterial concentration (107 to 100) (Fig. 2b). The mean
CT value for each bacterial concentration was determined and
a range set for each dilution as the mean CT  1 standard
deviation (SD) (Fig. 2c). Since the maximum spike tested was
107 bacilli, values for 108 bacilli ml1 were extrapolated from
the data obtained for 107 to 102 bacilli ml1 sputum. Using the
mean CT  1 SD, 100% of 10
7 to 102 (86 of 86 samples) were
within 1 log10, and 98% (84 of 86 samples) were within 0.5
log10 of the culture-defined bacterial count. Samples with10
2
bacilli ml1 were considered negative by this assay. Of 45
sputum samples spiked with 102 bacilli ml1, two were false
positives (4.4%) (Fig. 2c). The internal control was validated
empirically for cycle threshold values between 16 and 26.9.
Where the internal control gave a CT of 26.9, the sample was
considered too inhibited to give a valid bacterial load measure-
ment. Of 584 patient sputum samples included in this study,
only 4 (0.7%) were too inhibited to be assigned a value using
the MBL assay.
Rate of bacterial decline during the first 3 days of treatment
is rapid and dependent on bacterial load at day 0. To address
whether the 16S rRNA species used in the MBL assay re-
sponds rapidly to changes in the live-bacillus number, we an-
alyzed the decline of bacterial load measured with the MBL
assay during the first 3 days of treatment. All 16S rRNA data
were adjusted with the internal control as described above to
normalize for variations in the efficiency of the reaction and
RNA quality. Bacterial load could then be calculated in each
sample according to the range given in Fig. 2c. The mean
decline in bacterial load during the first 3 days was found to be
0.99 log10 (95% confidence interval [95% CI], 0.81 to 1.17) and
therefore a 90% reduction in mean bacterial load during this
time period (Fig. 3a to d), illustrating that 16S rRNA can
respond rapidly to bacterial decline.
Fifty-four of 103 patients (52%) had a 1.0 log10 decline
during the first 3 days of treatment (Fig. 4). Further analysis
found that the rate of decline in bacterial load during the first
3 days of treatment correlated with the bacterial load at day 0
(R2 0.12, P 0.0003, linear regression) (Fig. 4). This analysis
found that 93% of subjects with107 bacilli ml1 sputum (n
15) had a 1.0 log10 decline in bacterial load after 3 days of
treatment, whereas only 24% (n  21) of samples presenting
with5 104 bacilli ml1 sputum had a similar decline during
the same phase.
Longitudinal decline in bacterial load as measured using
the MBL assay was biphasic. In order to ascertain whether
measuring bacterial decline in response to treatment by using
the MBL assay is comparable to using solid culture, we ana-
lyzed the data using the same mathematical models previously
established for serial colony-counting (SSCC) studies (25). The
decline in MBL was found to be biphasic. A biexponential
mixed-effects model was found to best fit the data when com-
pared to either monoexponential or biexponential models (P
FIG. 2. (a to c) Optimization of the MBL assay. (a) Correlation
between detection of the internal control (IC) gene and tuberculosis
complex-specific 16S rRNA in 51 sputum samples, spiked with 107 M.
tuberculosis bacteria and 50 ng IC. (b) Cycle threshold (CT) range for
15 sputum samples spiked with serial dilutions of H37Rv. Cycle thresh-
old values were normalized against IC as determined in panel a using
the following equation: 16S rRNA CT  [(IC CT  16.00)  0.7834].
(c) Range of CT values specified for each concentration of H37Rv
(mean  SD) according to the analysis shown in panel b. The internal
control CT was validated between 16.00 and 26.9. Symbols: , value
extrapolated from other data; †, unnormalized CT values below 10.0
obtained in an RT-qPCR run were repeated as a 10-fold dilution.
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0.0001) (Fig. 5). This model has also been found to be the best
fit for SSCC data (4, 25). The triexponential model did not
converge, most likely since it was too complex for the limited
data.
Molecular count as an early biomarker of treatment re-
sponse. Further analysis using the nonlinear models found that
a model that differed by relapse status (model 4) better fit the
data than the pooled model (model 3) (P  0.0009). The key
difference was in the A parameter, reflecting the bacterial load
at day 0 (cured A  5.51, 95% CI, 5.28 to 5.74; relapse A 
6.70, 95% CI, 5.96 to 7.43; P  0.0002) (Fig. 5). There was no
significant improvement in model fit by allowing either gradi-
ent, 	 in the first phase or  in the second phase, to differ by
relapse status. Using logistic regression there was a clear as-
sociation between MBL-determined day 0 bacterial load and
relapse status, with an increased odds of relapse of 3.62 (95%
CI, 1.53 to 8.59) for every 1 log10 increase in day 0 bacterial
load.
Culture conversion at day 56 has gained wide currency as a
critical time point for treatment response and is the best cur-
rently available predictor of relapse (1). Previous studies have
suggested that 16S rRNA has a long half-life in sputum fol-
lowing bacterial death that would interfere with the value of
this measure as an endpoint (5). To address whether the MBL
assay is comparable to liquid culture during the second phase
() of bacterial elimination, the MBL assay data were com-
pared to liquid culture results obtained at day 56. There were
94 subjects where bacterial load data, measured by the MBL
assay and liquid culture, were available. Twenty-five of 26
samples at week 8 (96%) found to contain 103 bacilli ml1
sputum with the MBL assay were also culture positive (Ta-
ble 1). Ten samples found positive using the MBL assay
were negative by culture, and 24 samples were detected as
culture positive but were negative by the MBL assay at this
time point (Table 1).
DISCUSSION
The purpose of our work was to develop a rapid molecular
assay to quantify M. tuberculosis that can substitute for culture-
based methods and to validate it in a study of patient response
to chemotherapy. Such a method would be useful in simplify-
ing clinical trial methodology.
Many molecular tests are compromised by variability cre-
ated during nucleic acid extraction. To overcome these prob-
lems, we developed an improved internal control. A previous
study has reported the use of a 101-bp fragment from the phyB
gene in detecting inhibition during qPCRs. We demonstrated
that extraction and inhibition effects are comparable between
our 1,957-bp IC, but this was not case for the 101-bp fragment
(our unpublished data) and Mycobacterium tuberculosis 16S
rRNA when the 101-bp control was added prior to RNA ex-
traction. Using our internal control, it was possible to normal-
ize the RT-qPCR 16S rRNA data for robust detection of
bacteria in spot sputum samples containing between 108 and
102 bacilli ml1 sputum with up to 1,000-fold assay inhibition.
This is based on detection of the internal control using RT-
qPCR before and after spiking into the RNA extraction. A
cycle threshold of 7.00 was observed prior to extraction,
whereas the IC signal was not detected until at least cycle 16.00
after extraction. We found mRNA was not detected in samples
with 104 bacilli ml1 (5; our unpublished data), whereas the
limit of bacterial detection using the MBL assay was 102 bacilli
ml1 and therefore a significant improvement over mRNA (10,
FIG. 4. Decline in bacterial load during the early phase of bacterial
killing (day 0 to day 3) according to the presenting bacterial load.
FIG. 3. (a to d) MBL assay-determined bacterial load in patient
sputum samples collected longitudinally (days 0, 3, 7, 14, and 56) for 96
patients who had complete data sets for all of these time points and
who were on chemotherapy (bacterial load results were determined
using 16S rRNA and normalized against the IC; bacterial load values
were assigned according to Fig. 2c). Day 0 bacterial loads (ml1 spu-
tum): 1  107 to 5  107 (a), 1  106 to 5  106 (b), 1  105 to 5 
105 (c), and 5  104 (d).
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15). This is despite the observation that 16S rRNA may be
downregulated as bacteria enter dormancy (28).
A challenge to any molecular method is whether it is able to
detect changes in the numbers of organisms over short time
frames. We have shown that the mean decline in bacterial load
during the first 3 days was found to be 0.99 log10 (95% CI, 0.81
to 1.17), which suggests that the MBL assay does have the
ability to rapidly detect changes in numbers of organisms.
We performed nonlinear modeling of MBL assay data in
response to chemotherapy in order to assess how the assay
compared to culture-based methods. The decline in the first
phase of decay (	), 0.33 log10 per day, suggests that the 16S
rRNA concentration fell rapidly in line with bacterial killing.
Studies using solid agar have reported 	  0.52 log10 per day
(4, 25) when using the same biexponential mixed-effects model.
Unfortunately, we did not have solid culture colony counts
available for direct comparison.
Thus, we believe that the MBL assay has considerable utility
as a tool to understand the dynamics of treatment response.
For example, we found that the rate of decline of MBL assay-
determined bacterial load between days 0 and 3 was dependent
on the bacterial load at day 0. If the bacteria were killed at a
uniform rate, then the log decline should be the same regard-
less of the starting number. It may be that these differences are
FIG. 5. Mathematical modeling: MBL assay-determined bacterial decline for 111 patients using data from day 0 to day 56. The best-fit
mixed-effect biphasic decay model is shown, and data from 2 SSCC studies, those of Rustomjee et al. (25) and Davies et al. (4), which previously
found that the best fit was biphasic decay. Fit of nested sums of various exponential models. Parameters A and B are the intercepts for the phases
of killing (log10 bacterial load ml
1), and 	 and  are the corresponding rates of decrease in bacterial load (log10 bacterial load ml
1) as derived
from the model. a, Akaike information criterion—a lower number indicates a model that fits the data better; b, comparing models 1 and 2; c,
comparing models 2 and 3; d, comparing models 3 and 4; e, Wald test comparing parameter estimates between models for cured and relapse
patients.
TABLE 1. MBL assay-determined bacterial load compared to
culture positivity at day 56 for 94 patients where both
data were availablea
16S rRNA bacterial
load ml1 sputum
No. (%) of samples
Total Culture positive Culture negative
1  105 to 5  105 1 1 (100) 0 (0)
1  104 to 5  104 2 2 (100) 0 (0)
1  103 to 5  103 23 22 (96) 1 (4)
1  102 to 5  102 21 12 (57) 9 (43)
0 47 24 (51) 23 (49)
Total 94 61 33
a The limit of detection for the MBL assay was determined to be 102 bacilli
ml1. Therefore, assignment of 16S rRNA-determined bacterial load given as
negative in the table represents any bacterial load that was 102 ml1.
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attributable to the previously described heterogeneity of bac-
terial populations present in pretreatment sputum samples
(16). The presence of the two phases of bacterial killing has
previously been attributed to these heterogeneous populations
of bacteria responding differently to the chemotherapy, with
isoniazid killing rapidly dividing bacteria during the early treat-
ment phase (	) and the other antibiotics acting on the non-
replicating population during the second phase () (16, 19).
Higher bacterial load has previously been associated with the
extent of cavitation (23, 24), and it might be expected that
bacteria in the sputum expectorated by these patients would
have a higher proportion of bacteria in a state of rapid division.
Studies have also reported the presence of sputum bacteria
with a persister phenotype (7). Both the proportion and the
number of different bacteria in the lung may have an influence
on how the patient responds to chemotherapy.
Bacterial load at day 0 was a predictor of later relapse, which
mirrors liquid culture-based analysis in the same cohort
(12). The number of relapses in this study was small (12 of
111 patients), and further work is required to confirm and
strengthen this result.
When the MBL assay longitudinal data from 56 days of
treatment were analyzed, we found that a biexponential mixed-
effects model best described the data. Biphasic decay has been
described by different authors using solid agar for quantifica-
tion of bacterial load during treatment response (4, 25). The
point on the fitted line where the decline transitions from the
first phase (kill of rapidly dividing bacteria) to the second (kill
of persister bacteria) can be calculated mathematically from
the parameter estimates. This transition point occurs slightly
later when using the MBL assay, at 3.99 and 6.49 days for cured
and relapse, respectively. The transition points for the pub-
lished SSCC data can be calculated from the printed parame-
ter estimates, and these were 3.60 and 2.93 (4, 25). In these
cohorts, relapse follow-up data were not available. The transi-
tion times are relatively comparable considering that the data
came from different cohorts. Differences could be attributable
to variations such as HIV status in the patient groups or could
reflect the time taken for the 16S rRNA species to decay
following bacterial cell death or the detection of nonculturable
bacilli with the MBL assay.
For early bactericidal activity (EBA) studies and clinical
trials modeling bacterial clearance, it may be possible to adopt
the MBL assay in place of culture. However, the fact that both
liquid culture and the MBL assay detected positive samples at
day 56 when the other assay was negative suggests that the
detection of culture-negative status at this time point may be
improved by sample analysis with both assays. Culture-negative
samples detected positive using the MBL assay at day 56 could
be explained by viable bacilli that are refractive to culture
media, as noted in a previous study when longitudinal sputum
samples were tested for the presence of 16S rRNA during
treatment (21). Several studies have also found increased re-
covery in bacilli by culture when resuscitation factors are added
from exponential cultures (6, 22).
The advantages of the MBL assay reported here include
results being obtained within 24 h of sputum expectoration
regardless of bacterial load present, which contrasts to the long
time delay required for low-burden samples to be tested by
currently available culture-based methods. Also, 1% of sam-
ples were too inhibited when using the MBL assay, whereas
contamination with other organisms invalidates 4.4 to 8.6% of
liquid cultures depending on the method used (3). The speci-
ficity of our M. tuberculosis 16S primer and probe set to M.
tuberculosis complex was determined empirically by testing a
panel of 7 nontuberculosis bacteria and 5 other respiratory-
relevant species (see Data S2 in the supplemental material).
Our in vitro analysis calculated the false-positive rate of this
assay to be 4.4%, which is in line with a median of 3.1% for
culture false positives (interquartile range, 2.2% to 10.5%) (2).
In summary, we present a novel assay that is robust and
reproducible for the quantification of tubercle bacilli in sputum
samples. We believe that it will be of use in measuring treat-
ment response in clinical trials.
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